Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14099195 | 0.89 | HDAC1 (0.53) | MEN1KMT2ARXFP1MAPK14SMN1; SMN2 | |
| SCHEMBL13293399 | 0.88 | ESR1 (0.46) | MEN1KMT2ARXFP1MAPK14SMN1; SMN2 | |
| SCHEMBL9979308 | 0.86 | SMN1; SMN2 (0.48) | MEN1KMT2ARXFP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL10073270 | 0.84 | NR1H4 (0.44) | MEN1KMT2ARXFP1MAPK14SMN1; SMN2 | |
| SCHEMBL13293378 | 0.83 | TAS1R3 (0.52) | MEN1KMT2ARXFP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL13681508 | 0.83 | BRD4 (0.40) | MEN1KMT2ARXFP1MAPK14SMN1; SMN2 | |
| SCHEMBL1003870 | 0.83 | GAA (0.54) | MEN1KMT2ARXFP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL21241106 | 0.82 | HDAC6 (0.63) | MEN1KMT2ARXFP1MAPK14SMN1; SMN2 | |
| SCHEMBL4151138 | 0.82 | NR1H4 (0.61) | MEN1KMT2AMAPK14SMN1; SMN2MAPT | |
| SCHEMBL11642867 | 0.79 | L3MBTL1 (0.46) | MEN1KMT2ARXFP1MAPK14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687532-B2 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritis | GLAXOSMITHKLINE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7585861-B2 | HIV replication inhibitors; for (multi)drug resistant HIV infection | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-08 | — | — | US | disclosed |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | GLAXOSMITHKLINE LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070037811-A1 | HIV replication inhibitors; for (multi)drug resistant HIV infection | BMO BANK N.A., AS ADMINISTRATIVE AGENT | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037811-A1 | HIV replication inhibitors; for (multi)drug resistant HIV infection | REV1, CCNI, MCM6 | MEN1 4127/4885KMT2A 1659/4885RXFP1 4572/4885 |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | CNKSR1, MAPK1, MAPK7 | MEN1 4697/4885KMT2A 3665/4885RXFP1 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.